The FDA on December 17, 2025, approved RYBREVANT FASPRO® for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of RYBREVANT®. See the prescribing information for the specific indications. RYBREVANT FASPRO® is a product of Janssen Biotech, Inc.
Bottom Ad
Advertisement
Subscribe
